Welcome to our dedicated page for Iovance Biotherp SEC filings (Ticker: IOVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Iovance Biotherapeutics, Inc. filings document a biotechnology company focused on polyclonal TIL therapies, including disclosures tied to Amtagvi, Proleukin, lifileucel, and broader solid-tumor cell therapy programs. Its Form 8-K reports cover operating results, financial condition, corporate presentations, clinical or regulatory disclosures, and material-event updates.
The filing record also includes proxy materials covering director elections, executive compensation, shareholder voting matters, and board governance. Capital-structure disclosures include common stock matters, registration-statement references, and material agreements related to an at-the-market offering program.
Iovance Biotherapeutics is asking stockholders to approve seven proposals at its 2026 virtual-only annual meeting on June 10, 2026. Holders of 446,502,396 shares of common stock as of April 15, 2026 can vote online, by phone, mail, or during the webcast.
Stockholders will vote on re-electing six directors, an advisory “say on pay” for named executive officers, and how often to hold future say-on-pay votes. They will also consider ratifying Ernst & Young LLP as auditor for 2026, adding 1,000,000 shares to the 2020 Employee Stock Purchase Plan, increasing authorized common stock from 500,000,000 to 650,000,000 shares, and a potential adjournment to solicit more proxies if Proposal 6 lacks support.
Iovance Biotherapeutics, Inc. is soliciting proxies for its 2026 Annual Meeting to be held virtually at 11:00 a.m. Eastern on June 10, 2026. The record date is April 15, 2026, and 446,502,396 shares of common stock were outstanding as of that date. Agenda items include election of seven directors, ratification of Ernst & Young LLP as auditor, advisory "say on pay" votes, an increase to the 2020 Employee Stock Purchase Plan by 1,000,000 shares (Proposal 5), and a proposed amendment to increase authorized common shares from 500,000,000 to 650,000,000 (Proposal 6), with a related adjournment proposal (Proposal 7) to solicit additional proxies if needed.
Iovance Biotherapeutics Schedule 13G/A (Amendment No. 6) reports that The Vanguard Group holds 0 shares of Common Stock, representing 0% ownership. The filing explains an internal realignment effective January 12, 2026, after which certain Vanguard subsidiaries report beneficial ownership separately.
Iovance Biotherapeutics, Inc. reported that board member Wendy Yarno has notified the Board she will retire and will not stand for re-election at the company’s annual meeting of stockholders, which is anticipated to be held in June 2026.
Ms. Yarno will continue to serve as a director until the annual meeting. The company stated that her decision to retire is not due to any disagreement with Iovance regarding its operations, policies, or practices, and publicly thanked her for her service on the Board.
Roche Corleen M. reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Financial Officer, Corleen M. Roche, received a grant of 132,200 restricted stock units (RSUs) on common stock as equity compensation. Each RSU represents the right to receive one share of common stock if vesting conditions are met.
These RSUs vest over three years, with one-third vesting on the one-year anniversary of the grant date. The remaining RSUs then vest in eight equal quarterly installments over the following two years, provided she remains employed with the company on each vesting date.
Vogt Frederick G reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. granted Interim CEO & General Counsel Frederick G. Vogt 235,000 restricted stock units (RSUs) on March 9, 2026. Each RSU represents a contingent right to receive one share of Iovance common stock.
Vesting depends on continued employment. One-third of the RSUs will vest on the one-year anniversary of the grant date. The remaining RSUs will then vest in eight equal quarterly installments over the following two years, starting with the first quarter after the first anniversary.
Puri Raj K. reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. granted Chief Regulatory Officer Raj K. Puri 117,500 restricted stock units (RSUs) on common stock. Each RSU represents a right to receive one share if vesting conditions are met. The award vests over three years, with one-third vesting on the first anniversary of grant and the remaining two-thirds vesting in eight equal quarterly installments over the following two years, so long as he remains employed with the company.
GRAF FINCKENSTEIN FRIEDRICH reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. reported that its Chief Medical Officer, Friedrich Graf Finckenstein, received a grant of 58,750 restricted stock units. Each RSU represents a contingent right to receive one share of common stock.
The RSUs vest over three years, assuming continued employment. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years. After this grant, the reporting person holds 58,750 RSUs directly.
Kirby Daniel Gordon reported acquisition or exercise transactions in this Form 4 filing.
IOVANCE BIOTHERAPEUTICS, INC. Chief Commercial Officer Daniel Kirby received a grant of 132,200 restricted stock units. Each RSU represents a contingent right to receive one share of common stock. After this grant, he holds 132,200 RSUs.
The RSUs vest over three years if he remains employed. One-third vests on the one-year anniversary of the grant date, and the remaining units vest in eight equal quarterly installments over the following two years.
BILINSKY IGOR reported acquisition or exercise transactions in this Form 4 filing.
Iovance Biotherapeutics reported that Chief Operating Officer Igor Bilinsky received a grant of 117,500 restricted stock units. Each RSU represents one share of common stock. The award vests over three years, with one-third vesting after one year and the balance in eight quarterly installments.